glp-1 drugs covered by insurance Perspectives from employers on the costs and issues associated with covering agonists for weight loss States cutting back on coverage

Prescribing should follow current NICE guidance and licensing indications

Whats the difference between GLP-1 and tirzepatide (Mounjaro or Zepbound)

M., Gonzalez-Campoy, J

There are currently 21 vision loss lawsuits in the state pending before eight different judges

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

The shortage of supply of GLP-1 therapies in South Africa is said to be caused by the rise in demand for their off-label use